Wednesday, 30 November 2011

ThromboStep – designed for quantitation of platelet associated immunoglobulin using flow cytometry

Generally in humans, a normal platelet count ranges from 150,000 and 450,000 per ul. Thrombocytopenia is the presence of relatively few platelets in the blood. Decreased platelet counts can be due to a number of disease processes, the quantification of platelet associated immunoglobulin is a decreased ratio in platelet production or an increase in the ratio of destruction.

Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterised by a low platelet count and mucocutaneous bleeding. The autoantibodies are directed primarily to the platelet-specific receptors CD41a (GPIIb/IIIa) and CD42b (GPIb). As a result the sensitised platelets are rapidly cleared by the monocyte-macrophage cell systems.

The determination of autoantibodies against thrombocytes allows differentiation of immune from non-immune thrombocytopenia.

The kit contains:
  • Monoclonal antibody anti CD41a PE
  • FITC polyclonal antibody to total human immunoglobulin
  • FITC polyclonal antibody to human IgA
  • FITC polyclonal antibody to human IgM
  • FITC polyclonal antibody to human IgG
  • FITC conjugated polyclonal antibody to total rabbit immunoglobulins
  • Washing Buffer
(CE Marked)

Monday, 28 November 2011

FETALtrol: Assayed whole blood controls for confident foetal cell detection in maternal circulation

Laboratory determination of the level of foetal cells in maternal circulation remains an important support in the diagnosis and obstetrical management of women with suspected uterine trauma and in the proper dose administration of Rh Immune globulin (RhIg).

FETALtrol is an assayed, stabilized 3-level control set designed to validate and monitor the quality of procedures for the detection of Foeto-maternal haemorrhaging. It is compatible as a control for both manual (KBB) and flow cytometric methods.

“Good laboratory practice requires that controls be run with every batch of patient samples or at least once per day of analysis....Controls are ideally stabilized whole blood materials that can be used to provide precision monitoring of the analytical method.”

Clinical and Laboratory Standards Institute (formerly NCCLS) recommendations from document H52-A.

Key Benefits of FETALtrol:

  1. FETALtrol is CE marked as an IVD according to ISO13485:2003 and has been cleared by the FDA as a haematologic control (IVD) for foetal red cell detection.
  2. Eliminates the need to acquire cord blood and prepare 'home brew' controls, saving time and reducing exposure to untested potentially infectious material.
  3. Assayed values at three levels serve as both a quality measure for the assay method, as well as a reference material for proper gating.
  4. FETALtrol is a stabilized blood product that handles like patient blood samples.

Complimentary sample kits available - limited number. Email: to request a kit.

Product Code: FH102 - FETALtrol Sample Kit Pack Size: 25; Complimentary, conditions apply*

Product Code: IQP-370 FT – FETALtrol Pack Size: 50 test kit; £205

Download FETALtrol product information sheet

FETALtrol Production Schedule available on request, please email

*One complimentary kit per department. Limited stock available.

FETALtrol is an in vitro diagnostic reagent composed of D-antigen (Rho) negative human adult erythrocytes, supplemented with D-antigen (Rho) positive human cord blood erythrocytes.

Level 1 (N) - Normal or Negative

Level 2 (L) - Low Positive

Level 3 (H) - High Positive

Friday, 25 November 2011

Product Launch - OC-515 and CF Blue

New antibodies conjugated with new fluorochromes and new antibodies premixed derived from EuroflowTM.

Main characteristics of OC-515 and CF Blue:
  • Compatible with the standard filter sets of cytometers equipped with violet laser
  • Emission spectrum is narrow and well separated. Optimal stain index.
Both reagents are under the validation of the Euroflow and will be added to the recommended Euroflow reagents list. Reagents achieve the necessary quality to use in the study of biological samples such as Human Peripheral Blood or Human Bone Marrow.

OC-515 - an alternative to Pacific Orange
Does not present excitation detected in the 488nm laser, needs minimal compensation requirements

New reagents available conjugated with OC-515:
CD45OC-515 (clone GA90, isotype IgG2a)
CD138OC-515 (clone B-A38, isotype IgG1)

CF Blue - an alternative to Pacific Blue

New reagents available conjugated with CF Blue:
CD3CF Blue (clone GA60, isotype IgG1)
CD4CF Blue (clone H2P/6, isotype IgG2a)
CD20CF Blue (clone LT20, isotype IgG2a)

Friday, 18 November 2011

suPARnostic® - a Unique Prognostic Biomarker

suPAR (soluble urokinase plasminogen activating receptor) is a protein in the blood. The plasma level of suPAR reflects immune activation and is increased in several infectious diseases. High suPAR levels are associated with increased inflammation, disease progression and fatal outcome.

Measuring suPAR levels can serve as a marker to monitor disease progression and treatment [Ref. 1-6].

suPARnostic® is a Risk Status Marker, providing additional information regarding a patient, and acting as a master alarm for a patient’s risk status. An elevated suPARnostic® level reflects a developing critical condition.

suPAR levels can be measured easily with the novel suPARnostic® ELISA kit. This is a CE/IVD approved kit providing fast and reproducible results. By measuring an individual’s suPARnostic® level, the prognosis can be supported, the need for therapy is indicated and the effect of treatment can be monitored.

The suPARnostic® ELISA Assay is a simplified double monoclonal antibody sandwich assay where samples and peroxidase-conjugated anti-suPAR are mixed in white microwells prior to incubation in anti-suPAR precoated optically clear microwells. Performing the suPARnostic® ELISA involves two antibodies with high specificity for suPAR. The plasma sample with an unknown amount of suPAR is immobilized on the microwells on the clear microtiter plate and a detection antibody form a complex with suPAR.

Product Code: A001 - suPARnostic® Standard ELISA Assay
Product Code: A002 - suPARnostic® Flex ELISA Assay

  1. Sidenius N, Sier CFM, Ullum H, Pedersen BK, Cozzi LA, Blasi F, and Eugen-Olsen J, (2000) The American Society of Hematology, 96, 4091-4095
  2. Wittenhaugen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen SS, and Eugen-Olsen J, (2004) European Society of Clinical Microbiology and Infectious Diseases, 10, 409-415
  3. Østergaard C, Benfield T, Lundgren JD, and Eugen-Olsen J, (2004) Scand J Infect Dis, 36, 14-19
  4. Kofoed K, Eugen-Olsen J, Petersen J, Larsen K, and Andersen O, (2008) Eur J Clin Microbiol Infect Dis
  5. Ostrowski SR, Ullum H, Goka BQ, Høyer-Hansen G, Obeng-Adjei G, Pedersen BK, Akanmori BD, and Kurtzhals JAL, (2005) The Journal of Infectious Diseases, 191, 1331-1341
  6. Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse I, (2002) Int J Tuberc Lung Dis, 6, 686-692

Thursday, 17 November 2011

Mini-Exhibition at CIMR

We will be at the Cambridge Institute for Medical Research (CIMR) next Wednesday 23rd November from 10-4pm, why not come along and visit us.

The Cambridge Institute for Medical Research (CIMR) is a cross-departmental institute, within the University of Cambridge Clinical School, that is housed in the Wellcome Trust/MRC Building on the Addenbrooke's Hospital Site of the Cambridge Biomedical Campus.

It provides a unique interface between basic and clinical science that underpins its high level objective of determining and understanding the molecular mechanisms of disease. Currently, CIMR comprises approximately 250 scientists, about a quarter of who are graduate students.
They are organised into around 40 research groups each led by a Principal Investigator (PI) who, along with their group members, is also a member of one of seven home University departments (Medicine, Pathology, Medical Genetics, Clinical Biochemistry, Haematology or Clinical Neurosciences).

We’ll be located on Level 7 outside the lounge area. For your chance to win one of 5 Christmas Chocolate treats, pop by and visit us.

For more information on this mini-exhibition email:

Tuesday, 15 November 2011

Fastlink Conjugation Kits for One-Step Antibody Labelling

One-step process
30 seconds hands-on time
Scalable from µg to mg
100% recovery

Abnova have recently brought the Fastlink range of innovative antibody labelling and conjugation kits to the market. These kits allow elimination of the separation steps associated with antibody and protein labelling. The mixture of conjugate stabilizers and enzyme labels are provided in a lyophilized format. Addition of the antibody or protein solution to be labelled is required. Excess reactive chemicals then decay over several hours and by-products are benign in immunoassays.

Hands-on time for antibody conjugation is reduced to 30 seconds, and the performance of these enzyme-conjugated antibodies are as good as, or better than, those prepared with labour-intensive multistep conjugation protocols.

The overall procedure is completed within one vial, so this technique can be used to label small quantities of protein with 100% recovery, significantly minimizing the initial reagent amount and lowering development costs.
In traditional multistep protocols, 30 to 40 parameters need to be tightly controlled, impacting yield and reproducibility. Now, with the one-step labelling technology, researchers need only to control a few conjugation parameters, so the conjugation reactions are also relatively easy to scale up.

Fastlink Labelling Kits Available include:
Enzymes, Fluorescent Proteins, Fluorescent Dyes, Biotin, and Streptavidin
Applications include:
Western-Blotting, Immunohistochemistry, Immunofluorescence, ELISA, FACS, FRET

View the full range of labels available by clicking here.

Monday, 14 November 2011

World Diabetes Day - 14th November 2011

World Diabetes Day was jointly introduced by the World Health Organisation (WHO) and the International Diabetes Federation (IDF). The global diabetes awareness campaign was introduced amidst concern over an escalating diabetes epidemic.

November 14th is a significant date in the diabetes calendar because it marks the birthday of the man who co-discovered insulin, Frederick Banting. Banting discovered insulin in 1922, alongside Charles Best.

World Diabetes Day is internationally recognised and is now an official United Nations Day.

Diabetes Facts
Diabetes is really called Diabetes Mellitus
2.6 million people in the UK have diabetes
More than 180 million people worldwide have diabetes
Type 1 diabetes is managed using insulin injections or an insulin pump
90% of people with diabetes have type 2 diabetes
Type 2 diabetes is managed by diet, exercise and sometimes medication and insulin

Caltag Medsystems provide a number of diabetes research reagents. Here are some of the most popular ones with our customers…

Adiponectin ELISA Kit - a biomarker of insulin resistance and type 2 diabetes. Read more.

RBP4 ELISA Kit - retinol binding protein 4 is a marker for insulin resistance and microalbuminuria in insulin-resistant subjects. Read more.

FTO ELISA Kit – FTO (fat-mass and obesity-associated gene) and type-2 diabetes have been shown to have a confirmed association. The presence of the FTO rs9939609 allele has been found to positively correlate with other symptoms of the metabolic syndrome, including higher fasting insulin, glucose, and triglycerides, and lower HDL-cholesterol. Read more.

Tuesday, 8 November 2011

TransFix® from Cytomark

TransFix® is a preservative solution that maintains cellular integrity while at the same time preserving antigenicity. It can be used to preserve and stabilise body fluids including blood, CSF, bone marrow and fine needle aspirates. TransFix® treated samples are stable for up to 10 days when stored at 40C. TransFix® has been used extensively in the immune monitoring of HIV patients and in immunophenotyping. The launch of 3ml and 10ml vacuum blood collection tubes containing TransFix/EDTA has led to extensive use by clinical research organisations in support of international clinical trials.

Orfao et al (2009) researched the diagnosis of Leptomeningeal Disease and found that in up to 40% of samples cell lysis occurs before the sample can be tested . When stabilised with TransFix® all cell bearing samples can be diagnosed. This led to the conclusion that failure to use a preservative could result in 30% of adverse pathologies not being reported due to cell lysis.

Free samples are available for validation testing – please email for more information. For more information, publications and resources check out our website.

Orfao, A. et al (2009) ‘Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry’, Journal of Clinical Oncology, vol. 27, no. 9, 1462-1469

Monday, 7 November 2011

Diabetes and Obesity Conference, 10th November 2011

We will be exhibiting at the Diabetes and Obesity conference at the Sir Ambrose Fleming Lecture Theatre, UCL on Thursday 10th November.

The meeting includes lectures from top specialists in the field;
  • Defining and measuring the metabolic syndrome: trends in prevalence of cardio-metabolic syndrome. Professor Sir George Alberti, Imperial College London
  • Drug induced obesity: mechanisms and metabolic implications. Professor Gavin Reynolds, Sheffield Hallam University
  • The efficacy of incretin based medications for the treatment of obesity type 2 diabetes. Professor John Wilding, University of Liverpool
  • Fitness or weight loss: results of a lifestyle intervention programme in patients with established diabetes. Dr Robert Andrews, University of Bristol
  • And many more…!

For full details on the programme and details of how to register, please visit this website.

We look forward to seeing you there!

Thursday, 3 November 2011

HSV1-G and HSV2-G (Herpes Simplex Virus types 1 and 2) antibody test systems from MBL

The MBL-BION HSV1-G and HSV2-G (Herpes Simplex Virus types 1 or 2) antibody test systems are indirect fluorescent antibody assays for the qualitative and/or semi-quantitative determination of HSV IgG antibodies in human serum. They are intended for use as an aid in the diagnosis of primary infection, reinfection or reactivation of the latent virus, and also as a determination of immunological experience with HSV.

HSV1-G Positive HSV1-M Positive

The indirect fluorescent antibody (IFA) assay methods used in these test systems are carried out in two basic reaction steps:
Step 1 - Human serum is reacted with the antigen substrate. Antibodies, if present, bind to the antigen forming stable antigen-antibody complexes. If no antibodies are present, the complexes are not formed and serum components will be washed away.
Step 2 - Fluorescein labelled antihuman IgG antibody is added to the reaction site which binds with the complexes formed in step one. This results in a positive reaction of bright apple-green fluorescence when viewed with a fluorescence microscope. If no complexes are formed in step one, the fluorescein labelled antibody is washed away, exhibiting a negative result.
The indirect fluorescent antibody (IFA) assay method is a solid phase immunoassay and has an advantage over other methods of HSV antibody detection in that it is sensitive and it is able to differentiate between the various antibody classes.

Kits and Kit Components
  • HSV-1 IgG Antibody 120 Test Kit. Product Code: HS1G-120
  • HSV-2 IgG Antibody 120 Test Kit. Product Code: HS2G-120
  • HSV-1 Substrate Slide, twelve wells. Product Code: HS1-3012
  • HSV-2 Substrate Slide, twelve wells. Product Code: HS2-4012
  • HSV IgG Positive Control Serum, 0.5 ml. Product Code: HSG-3520
  • HSV Negative Control Serum, 0.5 ml. Product Code: HSN-3510
  • Conjugate, IgG with Counterstain, 3.5 ml. Product Code: CCG-9972
  • Mounting Medium, 3.5 ml. Product Code: MM-9985
  • PBS Packet, One Litre, Product Code: PBS-9990

Tuesday, 1 November 2011

ELISA Kits from Uscn

Uscn have a vast range of ELISA kits. This blog gives you a little more information about a few of their top sellers.

ELISA Kit for Connective Tissue Growth Factor (CTGF)

CTGF is a cysteine-rich, matrix-associated, heparin-binding protein. In vitro, CTGF mirrors some of the effects of TGF beta on skin fibroblasts, such as stimulation of extracellular matrix production, chemotaxis, proliferation and integrin expression. CTGF can promote endothelial cell growth, migration, adhesion and survival and is thus implicated in endothelial cell function and angiogenesis.

CTGF binds to perlecan, a proteoglycan which has been localised in synovium, cartilage and numerous other tissues. CTGF has been implicated in extracellular matrix remodelling in wound healing, scleroderma and other fibrotic processes, as it is capable of up regulating both matrix metalloproteinases and their inhibitors.

Product Code: E90010Hu

ELISA Kit for Platelet Activating Factor (PAF)

PAF is a potent phospholipid activator and mediator of many leukocyte functions, including platelet aggregation, inflammation, and anaphylaxis. It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction. It causes platelets to aggregate and blood vessels to dilate. Thus it is important to the process of hemostasis. At a concentration of 10-12M, PAF causes life threatening inflammation of the airways to induce asthma like symptoms. Toxins such as fragments of destroyed bacteria induce the synthesis of PAF, which causes a drop in blood pressure and reduced volume of blood pumped by the heart, which leads to shock and maybe death.

Product Code: E90526Hu

ELISA Kit for Fibroblast Growth Factor 23 (FGF23)

FGF23 is located on chromosome 12 and is composed of three exons. Mutations in FGF23 that render the protein resistant to proteolytic cleavage leads to increased activity of FGF23 and the renal phosphate loss found in the human disease autosomal dominant hypophosphatemic rickets. FGF23 is also overproduced by some types of tumours, causing tumour-produced osteomalacia. Loss of FGF23 activity is thought to lead to increased phosphate levels and the clinical syndrome of familial tumour calcinosis. This gene was identified by its mutations associated with autosomal dominant hypophosphatemic rickets. Prior to discovery in 2000, it was hypothesized that a protein existed which performed the function of FGF23. This putative protein was known as phosphatonin.

Product Code: E90746Hu

Webmaster: AnnWebCom | Site design: Creative Copyright 2005-2015 Caltag-Medsystems Limited - all rights reserved